Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 422

1.

Atypical amplification of chromosome region 22q12 in melanoma: A case report.

Liguori G, Cantile M, Collina F, Marra L, DE Chiara A, Franco R, Caraglia M, Botti G, D'Andrea M, Nicoletti GF.

Oncol Lett. 2015 Jul;10(1):349-353. Epub 2015 Apr 27.

2.

Chin Microgenia: A Clinical Comparative Study.

Bertossi D, Galzignato PF, Albanese M, Botti C, Botti G, Nocini PF.

Aesthetic Plast Surg. 2015 Jul 1. [Epub ahead of print]

PMID:
26130400
3.

Determination of whether screening tests for chronic atrophic gastritis really has a positive predictive value.

Di Paola F, D'Angelo V, Tatangelo F, Barchiesi V, Rizzo M, Cantile M, Botti G, Cavalcanti E.

Mol Med Rep. 2015 Sep;12(3):3521-4. doi: 10.3892/mmr.2015.3872. Epub 2015 Jun 2.

PMID:
26035809
4.

Brooke-Spiegler syndrome presenting multiple concurrent cutaneous and parotid gland neoplasms: Cytologic findings on fine-needle sample and description of a novel mutation of the CYLD gene.

Malzone MG, Campanile AC, Losito NS, Longo F, Perri F, Caponigro F, Schiavone C, Ionna F, Maiello F, Martinuzzi C, Nasti S, Botti G, Fulciniti F.

Diagn Cytopathol. 2015 Aug;43(8):654-8. doi: 10.1002/dc.23275. Epub 2015 May 21.

PMID:
25995191
5.

AXL is an oncotarget in human colorectal cancer.

Martinelli E, Martini G, Cardone C, Troiani T, Liguori G, Vitagliano D, Napolitano S, Morgillo F, Rinaldi B, Melillo RM, Liotti F, Nappi A, Bianco R, Berrino L, Ciuffreda LP, Ciardiello D, Iaffaioli V, Botti G, Ferraiolo F, Ciardiello F.

Oncotarget. 2015 Apr 29. [Epub ahead of print]

6.

Synchronous Pleomorphic Adenoma and Invasive Ductal Carcinoma in Distinct Breasts.

Di Bonito M, Cantile M, Cerrone M, Liguori G, Botti G.

Breast J. 2015 Jul;21(4):428-30. doi: 10.1111/tbj.12426. Epub 2015 May 3. No abstract available.

PMID:
25940209
7.

Midface rejuvenation: a critical evaluation of a 7-year experience.

Pascali M, Botti C, Cervelli V, Botti G.

Plast Reconstr Surg. 2015 May;135(5):1305-16. doi: 10.1097/PRS.0000000000001189.

PMID:
25919244
8.

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.

Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; CAPRI-GOIM investigators.

Ann Oncol. 2015 Aug;26(8):1710-4. doi: 10.1093/annonc/mdv176. Epub 2015 Apr 7.

9.

Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.

Mozzillo N, Pasquali S, Santinami M, Testori A, Di Marzo M, Crispo A, Patuzzo R, Verrecchia F, Botti G, Montella M, Rossi CR, Caracò C.

Eur J Surg Oncol. 2015 Jul;41(7):823-9. doi: 10.1016/j.ejso.2015.02.005. Epub 2015 Mar 11.

PMID:
25800935
10.

Combined papillary and mucoepidermoid carcinoma of the thyroid gland: a possible collision tumor diagnosed on fine-needle cytology. Report of a case with immunocytochemical and molecular correlations.

Fulciniti F, Vuttariello E, Calise C, Monaco M, Pezzullo L, Chiofalo MG, Di Gennaro F, Malzone MG, Campanile AC, Losito NS, Botti G, Chiappetta G.

Endocr Pathol. 2015 May;26(2):140-4. doi: 10.1007/s12022-015-9364-9.

PMID:
25771987
11.

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas.

Manca A, Lissia A, Capone M, Ascierto PA, Botti G, Caracò C, Stanganelli I, Colombino M, Sini M, Cossu A, Palmieri G.

J Transl Med. 2015 Jan 28;13:37. doi: 10.1186/s12967-015-0401-8.

12.

HtrA1 loss is related to aggressive behavior parameters in sentinel node positive breast cancer.

Franco R, Collina F, Di Bonito M, Botti G, Montanaro D, Di Maio L, Vincenzi B, Landi G, D'Aiuto M, Caraglia M, Baldi A.

Histol Histopathol. 2015 Jun;30(6):707-14. doi: 10.14670/HH-30.707. Epub 2014 Dec 22.

PMID:
25530301
13.

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.

Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo MC, Signoriello S, Gallo C, de Matteis A.

Ann Oncol. 2015 Apr;26(4):675-82. doi: 10.1093/annonc/mdu564. Epub 2014 Dec 8.

PMID:
25488686
14.

Ran signaling in melanoma: implications for the development of alternative therapeutic strategies.

Caputo E, Wang E, Valentino A, Crispi S, De Giorgi V, Fico A, Ficili B, Capone M, Anniciello A, Cavalcanti E, Botti G, Mozzillo N, Ascierto PA, Marincola FM, Travali S.

Cancer Lett. 2015 Feb 1;357(1):286-96. doi: 10.1016/j.canlet.2014.11.033. Epub 2014 Nov 20.

PMID:
25444926
15.

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, Tatangelo F, D'Angelo V, Granata C, Cavalcanti E, Maurea N, Maiolino P, Bianco F, Montano M, Silvestro L, Terranova Barberio M, Roca MS, Di Maio M, Marone P, Botti G, Petrillo A, Daniele G, Lastoria S, Iaffaioli VR, Romano G, Caracò C, Muto P, Gallo C, Perrone F, Budillon A.

BMC Cancer. 2014 Nov 24;14:875. doi: 10.1186/1471-2407-14-875.

16.

KIT genetic alterations in anorectal melanomas.

Santi R, Simi L, Fucci R, Paglierani M, Pepi M, Pinzani P, Merelli B, Santucci M, Botti G, Urso C, Massi D.

J Clin Pathol. 2015 Feb;68(2):130-4. doi: 10.1136/jclinpath-2014-202572. Epub 2014 Nov 14.

PMID:
25398993
17.

Borderline Brenner tumor of the ovary: a case report with immunohistochemical and molecular study.

De Cecio R, Cantile M, Collina F, Marra L, Santonastaso C, Scaffa C, Botti G, Losito NS.

J Ovarian Res. 2014 Oct 29;7:101. doi: 10.1186/s13048-014-0101-7.

18.

Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype.

Capasso I, Esposito E, de Laurentiis M, Maurea N, Cavalcanti E, Botti G, Petrillo A, Montella M, D'Aiuto M, Coppola C, Crispo A, Grimaldi M, Frasci G, Fucito A, Ciliberto G, D'Aiuto G.

Diabetol Metab Syndr. 2014 Sep 26;6(1):105. doi: 10.1186/1758-5996-6-105. eCollection 2014.

19.

Role of the cystathionine γ lyase/hydrogen sulfide pathway in human melanoma progression.

Panza E, De Cicco P, Armogida C, Scognamiglio G, Gigantino V, Botti G, Germano D, Napolitano M, Papapetropoulos A, Bucci M, Cirino G, Ianaro A.

Pigment Cell Melanoma Res. 2015 Jan;28(1):61-72. doi: 10.1111/pcmr.12312. Epub 2014 Oct 6.

PMID:
25205294
20.

Midface lift: our current approaches.

Botti G, Botti C.

Handchir Mikrochir Plast Chir. 2014 Aug;46(4):224-33. doi: 10.1055/s-0034-1385927. Epub 2014 Aug 27. Review.

PMID:
25162240
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk